Johnson & Johnson Shares Outstanding 2006-2018 | JNJ

Johnson & Johnson shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Johnson & Johnson shares outstanding for the quarter ending September 30, 2018 were 2.728B, a 0.37% decline year-over-year.
  • Johnson & Johnson 2017 shares outstanding were 2.745B, a 1.56% decline from 2016.
  • Johnson & Johnson 2016 shares outstanding were 2.789B, a 0.85% decline from 2015.
  • Johnson & Johnson 2015 shares outstanding were 2.813B, a 1.78% decline from 2014.
Johnson & Johnson Annual Shares Outstanding
(Millions of Shares)
2017 2,745
2016 2,789
2015 2,813
2014 2,864
2013 2,877
2012 2,813
2011 2,775
2010 2,789
2009 2,789
2008 2,836
2007 2,911
2006 2,961
2005 3,003
Johnson & Johnson Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 2,728
Q2 2018 2,721
Q1 2018 2,732
Q4 2017 2,745
Q3 2017 2,738
Q2 2017 2,742
Q1 2017 2,755
Q4 2016 2,789
Q3 2016 2,785
Q2 2016 2,794
Q1 2016 2,804
Q4 2015 2,813
Q3 2015 2,807
Q2 2015 2,812
Q1 2015 2,826
Q4 2014 2,864
Q3 2014 2,864
Q2 2014 2,874
Q1 2014 2,875
Q4 2013 2,877
Q3 2013 2,881
Q2 2013 2,893
Q1 2013 2,859
Q4 2012 2,813
Q3 2012 2,818
Q2 2012 2,798
Q1 2012 2,775
Q4 2011 2,775
Q3 2011 2,778
Q2 2011 2,781
Q1 2011 2,773
Q4 2010 2,789
Q3 2010 2,786
Q2 2010 2,796
Q1 2010 2,797
Q4 2009 2,789
Q3 2009 2,793
Q2 2009 2,782
Q1 2009 2,790
Q4 2008 2,836
Q3 2008 2,831
Q2 2008 2,845
Q1 2008 2,866
Q4 2007 2,911
Q3 2007 2,913
Q2 2007 2,923
Q1 2007 2,924
Q4 2006 2,961
Q3 2006 2,948
Q2 2006 2,974
Q1 2006 2,993
Q4 2005 3,003
Q3 2005 3,006
Q2 2005 3,025
Q1 2005 3,024
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $393.045B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $261.986B 14.77
Merck (MRK) United States $207.903B 18.02
Novartis AG (NVS) Switzerland $201.478B 17.27
AbbVie (ABBV) United States $132.627B 11.77
Eli Lilly (LLY) United States $121.292B 21.32
Sanofi (SNY) France $111.158B 13.76
Novo Nordisk (NVO) Denmark $110.447B 17.94
AstraZeneca (AZN) United Kingdom $97.922B 12.16
GlaxoSmithKline (GSK) United Kingdom $92.650B 12.45
Bristol-Myers Squibb (BMY) United States $85.576B 14.09